Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit

What happened

Akari Therapeutics announced that Satyajit Mitra, its Head of Oncology, will present at the 3rd Annual ADC Payload Summit, held November 4–6, 2026, in Boston. The talk will explore RNA-splicing payloads as an alternative antibody drug conjugate mechanism.

Confirmed

Global impact / market context

If RNA-splicing payloads work, Akari could offer drugmakers a payload that kills cancer cells and also triggers immune responses, unlike standard payloads. That difference could support new partnerships or licensing deals, since partners may pay for access to differentiated technology.

Analyst inference

Antibody drug conjugates, which are treatments that attach a toxic payload to an antibody, mostly use microtubule or topoisomerase inhibitor payloads. Akari is positioning its RNA-splicing approach as an alternative. Success would depend on preclinical data translating into human trials, which has not yet happened.

Analyst inference

What to watch

1. The presentation is scheduled for November 4–6, 2026, in Boston, covering scientific rationale, engineering considerations, and preclinical evidence for RNA-splicing payloads. Confirmed
2. Akari proposes its PH1 payload, a spliceosome modulator that disrupts RNA splicing, could kill cancer cells while activating innate and adaptive immune responses. Proposed
3. Investors should watch whether the presentation discloses new preclinical data or partnership interest, because without human trial results the commercial value of the payload remains unproven. Analyst inference

Evidence

• globenewswire.com